Physician profile
Mark Versland
NPI 1639164775
$3,356.11
in general payments reported to CMS, 2019-2025
29 companies · $1,179 in 2025
The $1,179 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $457 · 2020: $87.73 · 2021: $11.73 · 2022: $124 · 2023: $531 · 2024: $966 · 2025: $1,179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,641 · Education: $34.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,641.09 |
| Education | $34.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $913.25 | 2019-2025 | Skyrizi, Creon, Linzess |
| Janssen Biotech, INC. | $340.19 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $255.84 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Phathom Pharmaceuticals, INC. | $202.85 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $188.71 | 2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $180.29 | 2019-2023 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $137.34 | 2022-2024 | Ocaliva |
| Celgene Corporation | $130.31 | 2022-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $125.58 | 2023-2025 | Dupixent |
| Gilead Sciences, INC. | $111.02 | 2020-2025 | |
| Genzyme Corporation | $110.52 | 2022-2025 | |
| Pfizer INC. | $104.70 | 2019-2024 | |
| Ferring Pharmaceuticals INC. | $61.62 | 2022-2025 | Rebyota |
| Daiichi Sankyo INC. | $55.36 | 2023 | Injectafer |
| Allergan, INC. | $54.90 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $44.19 | 2024 | Ibsrela |
| Shire North American Group INC | $40.28 | 2019 | |
| Fujifilm Healthcare Americas Corporation | $39.23 | 2023 | |
| Nestle Healthcare Nutrition INC. | $34.96 | 2023 | |
| Lilly USA, LLC | $34.22 | 2025 | Omvoh |
| Aimmune Therapeutics, INC. | $31.95 | 2025 | Zenpep |
| Evoke Pharma, INC. | $27.53 | 2024-2025 | |
| Ironwood Pharmaceuticals, INC | $27.39 | 2020-2023 | Linzess |
| Celltrion USA INC. | $25.07 | 2025 | Vegzelma |
| Novo Nordisk INC | $24.51 | 2025 | Wegovy |
| Exact Sciences Corporation | $22.93 | 2025 | Cologuard Collection Kit |
| Intra-Sana Laboratories | $22.09 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Qol Medical, LLC | $9.28 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$77,759.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Versland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.